Cell and Gene Therapy
Article: How Critical is Logistics to the Development of the Advanced Therapy Market?
Article: Per Dose Impact of Logistics on Advanced Therapies
The impact of logistics on the ability of advanced therapies to treat patients reinforces the message that therapy developers need to think about their entire supply chain and ‘Logistics by Design’ .
Article: Advanced Therapy Commercial Supply Chain Lessons for Clinical Trial Success
Article: How to Ensure the Safety of a Cell and Gene Therapy Product During Shipping
White Paper: Logistics by Design - a Framework for Advanced Therapy Developers
Executive Summary: Logistics by Design - a Framework for Advanced Therapy Developers to Create Optimal Logistics Platforms
Logistics by Design (LbD) is a framework for logistics decision making. Using a risk based analysis it identifies the areas within the supply chain that need to be addressed to create a logistics platform that can meet the needs of patients at clinical and commercial scale.
Article: Logistics in Cell and Gene Therapy; as Complex as the Myth Suggests?
Article: The Commercialization of Cell and Gene Therapies: Supplying Patients in Need
Article: Lessons Learned in the Evolution of Advanced Therapy Logistics
Article: Four Trends in Advanced Therapy Logistics and Their Impact on Customs Clearance
Webinar on-demand: Scalable Logistics for Cell and Gene Therapies
Video: Logistics Leaders: Connecting Cell and Gene Therapies to Patients
White Paper: 13 Ways Logistics Specialists are Transforming Cell and Gene Therapy Supply Chains
Article: What's Your Logistics Vision
Every CEO will be able to describe their target patient population, their clinical capability and their strategy for developing a manufacturing process, but how many can describe their strategy for connecting all of this to the patient? That is, what is their logistics vision?
Article: Silos: A Barrier to Cell and Gene Therapy Commercialization
Article: Our FACT-JACIE Standards Compliance
Article: GDP - The Critical Link in Maintaining Quality from GMP to the Patient
Article: Scaling to Commercial Viability for Cell and Gene Therapies
Article: Cell and Gene Therapy: the Teenage Years
Take a look at the recent development of Cell and Gene Therapy and how this relatively new medical field will see patients benefiting for years to come.
Article: Delivering a Cost Effective, Practical and Robust Cell Therapy Supply Chain
Overcoming logistical challenges through technology
Article: World Courier to support Advanced Therapies Treatment Centres (ATTCs)
Specialist centres will create and deliver systems to progress advanced therapy development through joint ventures set up by industry, academic and NHS partners
Article: An Interview with Sam Herbert
Sam Herbert, President of World Courier, gives insight into how cell and gene therapies can present new and difficult challenges for manufacturers and what can be done to support manufacturers from a supply chain perspective
Article: How Are Cell and Gene Therapies Challenging Pharma Logistics?
You’re investing hundreds of millions of dollars to develop products to enhance patient care and improve global health. But can your logistics partner meet the challenges?
Article: The Logistics Link in Successful Cell and Gene Therapy Trials
The success of a clinical study depends on the CRO’s or sponsor’s ability to bring together people, processes, and technology in a coordinated effort to improve patient outcomes, one case at a time.
Webinar on-demand: Practical Aspects of Shipping Cell and Gene Therapies
In this webinar on-demand World Courier’s Cell and Gene Therapy specialists share their knowledge with you, and discuss how our practical experience of Cell and Gene shipments is evolving logistics.
Article: Beyond Compliance to Excellence
E-book: Tomorrow's Medicine - Curing One Patient at a Time
To help you understand why personalized therapies require a personalized supply chain, we’ve published Tomorrow’s Medicine: Curing One Patient at a Time – an e-book highlighting the logistics challenges of cell and gene therapies.